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Phosphodiesterase inhibitors possess anti-in£ammatory
and immunomodulatory properties and seem to have a
great potential in the treatment of in£ammatory skin
diseases; however, an overall study on the e¡ects of spe-
ci¢c phosphodiesterase inhibitors, such as rolipram on
the processes involved in the extravasation of lymphoid
cells has not been performed. In this work we have as-
sessed the e¡ect of rolipram on the adhesion, polariza-
tion, and migration of normal human T lymphocytes.
We found that low concentrations of rolipram were able
to inhibit signi¢cantly the adhesion of T cells to the b1
and b2 integrin ligands vascular cell adhesion molecule-
1 and intercellular adhesion molecule-1. Rolipram also
interfered with the activation of integrins, and signi¢-
cantly inhibited the homotypic aggregation of T lym-
phocytes induced by anti-b1 and anti-a4 integrin chain
monoclonal antibodies. In addition, rolipram had a
downregulatory e¡ect on the activation of T cells,
and signi¢cantly diminished the expression of the acti-
vation antigens CD69, CD25, and CD98 induced by
phytohemagglutinin. Finally, this drug inhibited the
polarization and transendothelial migration of T lym-
phocytes induced by the chemokine CXCL12 (SDF-1)
and the chemotactic cytokine interleukin-15.The results
indicate that rolipram, at low concentrations, exerts an
important anti-in£ammatory and immunomodulatory
e¡ect, and suggest that this selective phosphodiesterase
inhibitor may be an e¡ective tool for the therapy of
immune-mediated diseases. Key words: cell adhesion/
chemokines/in£ammation/integrins/phosphodiesterase. J Invest
Dermatol 121:81 ^87, 2003
L
eukocyte^endothelial cell interactions play a crucial
part in di¡erent biologic phenomena, such as lympho-
cyte homing and in£ammation. During the in£amma-
tion process, endothelial cells become activated and
increase their expression of adhesion molecules, which
allow their interaction with blood leukocytes. The accumulation
of leukocytes into in£amed tissues occurs as a consequence of the
transendothelial migration of these cells and their subsequent
movement to the in£ammatory foci (Gonza¤ lez-Amaro et al,
1998a; Gonza¤ lez-Amaro and Sa¤ nchez-Madrid, 1999). The process
of leukocyte extravasation involves a cascade of adhesive events
between leukocytes and endothelial cells. Initially, circulating
leukocytes tether to and roll over activated endothelium, which
express adhesion molecules such as intercellular adhesion mole-
cule (ICAM)-1, vascular adhesion molecule (VCAM)-1, and E-
selectin. Then, leukocytes become activated by chemokines that
induce the activation of leukocyte integrins, allowing the ¢rm
adhesion of these cells to the endothelium. Finally, leukocytes
migrate between the endothelial cells and move through the ex-
tracellular matrix towards the in£ammatory foci (D|¤ az-Gonza¤ lez
and Sa¤ nchez-Madrid, 1998).
In order to migrate, lymphocytes require to be activated and
become polarized. During the interaction of lymphocytes with
endothelial cells and extracellular matrix, chemokines induce
the polarization of T lymphocytes, with the generation of two
specialized compartments, the leading edge at the front of the
cell, and the uropod, at the back end (del Pozo et al, 1998). The
chemokine receptors involved in the detection of chemoattractant
gradients are concentrated at the leading edge of the cell, whereas
adhesion molecules such as ICAM-1, ICAM-3, CD44, and CD43
are redistributed to the uropod (del Pozo et al, 1998). It has been
shown that the uropod is involved in the recruitment of bystan-
der leukocytes through LFA-1/ICAM-1-dependent cell^cell in-
teractions (del Pozo et al, 1997). Chemokines play a key part in
the activation and chemotaxis of leukocytes. Lymphocyte migra-
tion is induced by di¡erent chemokines such as CCL5
(RANTES), CCL3 (MIP-1a), and CCL2 (MCP-1) (DeVries
et al, 1995; Moser and Loetscher, 2001). In addition, the stromal
cell-derived factor 1 (SDF-1 or CXCL12) is involved in the che-
motaxis of lymphocytes towards in£amed tissues as well as in
the migration of these cells to lymph nodes (Nanki et al, 2000;
Zlotnik and Yoshie, 2000; Phillips and Ager, 2002). Other che-
motactic factors, such as interleukin (IL)-15 have been shown to
induce lymphocyte migration and cell polarization (Wilkinson
and Liew, 1995).
Cyclic adenosine monophosphate (cAMP) has been shown to
modulate in£ammatory and immune processes (Bourne et al,
1974). Phosphodiesterase (PDE) inhibitors increase intracellular
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cAMP by blocking cAMP conversion to 50AMP. Although
several PDE are present in immune cells (e.g., PDE3, PDE4,
and, to a lesser extent, PDE7), PDE4 seems to be the major con-
tributor to cAMP hydrolysis in lymphocytes, monocytes, poly-
morphonuclear leukocytes, basophils, and eosinophils (Torphy,
1998). Rolipram is a speci¢c inhibitor of PDE4, an enzyme that
exclusively hydrolyzes cAMP (Bolger et al, 1993). Rolipram exerts
complex immunomodulatory e¡ects. It has been shown that this
drug has a bene¢cial e¡ect in experimental autoimmune ence-
phalomyelitis (Mart|¤ nez et al, 1999), collagen-induced arthritis
(Ross et al, 1997) as well as in airways in£ammation and hyperre-
sponsiveness (Kanehiro et al, 2001). In addition, it has been
reported that rolipram regulates cytokine synthesis through
inhibition of nuclear factor-kB and NFAT transcription factors
(JimeŁ nez et al, 2001). On the other hand, rolipram has been de-
scribed to inhibit the adhesion of neutrophils to endothelial cells
(Derian et al, 1995) as well as the allergen-induced migration of
eosinophils (Silva et al, 2001). Furthermore, the staphylococcal en-
terotoxin B-induced expression of the T cell skin homing recep-
tor CLA is inhibited by rolipram (Santamaria et al, 1999). In
addition, several e¡ects of rolipram on endothelial cells have been
described (Blease et al, 1998; Folcik et al, 1999).
The potential role of PDE inhibitors in the therapy of im-
mune-mediated skin diseases has been previously explored. Pen-
toxifylline, a nonspeci¢c PDE inhibitor, seems to be of value in
the therapy of in£ammatory conditions such as graft versus host
disease, Schamberg’s disease, leprosy reaction, and allergic hyper-
sensitivity reactions (Samlaska and Win¢eld, 1994; Kano et al,
1997; Moraes et al, 2000). In vitro, this drug has di¡erent downre-
gulatory e¡ects on leukocytes, including tumor necrosis factor
(TNF)-a synthesis, cell adhesion and migration (Wang et al,
1997; Gonza¤ lez-Amaro et al, 1998b; Dom|¤ nguez-JimeŁ nez et al,
2002). The levels of pentoxifylline required to exert these e¡ects,
however, are high and it is not clear that these concentrations are
reached in vivo. Therefore, it is of interest to make an overall as-
sessment of the in vitro anti-in£ammatory properties of other
PDE inhibitors that have higher potency and a selective e¡ect
on the PDE expressed by lymphocytes. The aim of this work
was to explore the e¡ect of the PDE4-speci¢c inhibitor rolipram
on key phenomena involved in in£ammation.We found that this
drug exerts, at low concentrations, a downregulatory e¡ect on
lymphocyte activation, polarization, adhesion, and transendothe-
lial migration.These data strongly support the anti-in£ammatory
and immunomodulatory potential of this drug.
MATERIALS AND METHODS
Cells Peripheral blood mononuclear cells were isolated from healthy
donors by Ficoll-Hypaque gradient centrifugation. T lymphoblasts were
obtained by removing non-T cells from the peripheral blood
mononuclear cells by nylon wool adherence, and stimulating with 5 mg
per mL phytohemagglutinin (PHA-P; Sigma, St Louis, Missouri) for 48
h. Then, cells were washed and cultured in RPMI 1640 medium
(Whittaker,Walkersville, Maryland) containing 10% fetal calf serum and
25 U per mL IL-2 (R&D Systems, Minneapolis, Minnesota). T
lymphoblasts cultured for 2 to 4 d were typically used in all experiments.
Freshly isolated T lymphocytes were obtained from peripheral blood
mononuclear cells by rosetting with sheep red blood cells. Cell viability
was assessed by trypan blue dye exclusion and the percent of apoptotic
cells was determined by TUNEL (terminal deoxynucleotidyl transferase-
mediated deoxyuridine triphosphate nick end-labeling) and £ow
cytometry using the APO-DIRECT staining kit (Phoenix Flow Systems,
San Diego, California), according to the manufacturer’s instructions.
Antibodies, cytokines, and reagents Rolipram was obtained from
Sigma and was used from 107 to 103 M. The T3b anti-CD3, TP1/55
anti-CD69, TP1/6.2 anti-CD25, TP1/24 anti-ICAM-3, FG1/8 anti-CD98,
and the Lia1/2 anti-b1, and HP1/7 anti-a4 integrin chains as well as the
blocking TP1/40 anti-CD11a and HP1/2 anti-a4 integrin chain
monoclonal antibodies (MoAb) were kindly provided by Dr F. Sa¤ nchez-
Madrid, Hospital de La Princesa (Madrid, Spain), and have been
previously described (Cebria¤ n et al, 1988; Campanero et al, 1992, 1993;
Melero et al, 1993). The TS2/16 is an activating anti-b1 integrin MoAb that
has been previously described (Hemler et al, 1984). The HUTS-21MoAb is
speci¢c for an activation epitope of b1 integrins (Luque et al, 1996), and was
a generous gift of Dr C. Caban as, Consejo Superior de Investigaciones
Cient|¤ ¢cas (Madrid, Spain). Chimeric ICAM-1-Fc, and VCAM-1^4D-Fc,
consisting of the total extracellular domains fused to IgG Fc fragment,
were obtained as described (Berendt et al, 1992). Phorbol myristate acetate
(PMA) andTNF-awere purchased from Sigma, and IL-15 from Immunex
Corp. (Seattle, Washington). CXCL12 (SDF-1) was obtained from
PeproTech (Rocky Hill, New Jersey).
Cell adhesion assays Cell adhesion assays were performed as previously
described (Campanero et al, 1993; Luque et al, 1996). Brie£y, 96-well
microtiter EIA II-Linbro plates (Costar, Cambridge, Massachusetts) were
coated with recombinant chimeric ICAM-1-Fc (10 mg per mL), or
VCAM-1-4D-Fc (5 mg per mL), and nonspeci¢c binding sites were
saturated with 1% human serum albumin. Then, plates were washed three
times with PBS and 1105 T lymphoblasts or freshly isolated T cells,
previously incubated in the presence or absence of 10^5 M rolipram and
then treated or not with PMA, were added to each well. After
centrifugation at 10 g for 5 min, plates were incubated at 371C for 20
min. To quantify cell attachment, the plates were washed thrice with
RPMI 1640, and cells were ¢xed with methanol/acetone (1:1), and stained
with violet crystal 0.5%. Violet crystal was then extracted with sodium
citrate 0.1 M, pH 4.2/ethanol, and absorbance at 540 nm was measured in
a Multiskan EX ELISA reader (Labsystems Oy, Helsinki, Finland). All
assays were run in duplicate, and results were expressed as the percentage
of bound cells. The absorbance of 1105 cells, which were ¢xed and
stained without previous washing, was considered as 100% of cell
adhesion. Speci¢city of cell adhesion was corroborated using blocking
MoAb (TP1/40 anti-CD11a and HP1/2 anti-a4 integrin chains) or bovine
serum albumin as substratum.
Cell aggregation assays Homotypic cell aggregation assays were
performed as previously described (Campanero et al, 1993). Brie£y, T
lymphocytes (1105) pretreated or not with 10^5 M rolipram for 24 h,
were incubated in £at-bottom 96-well microtiter plates (Costar) in a ¢nal
volume of 100 mL of complete RPMI 1640 medium. Then, the pro-
aggregatory Lia1/2 anti-b1 and the HP1/7 anti-a4 integrin chain MoAb
were added at a concentration of 5 mg per mL, and cells were allowed to
settle at 371C for 3 h. Cell aggregation was determined by direct
visualization of the plate with an inverted microscope and counting the
free cells of at least ¢ve randomly chosen ¢elds. All assays were conducted
by duplicate and results were expressed as percentage of aggregated
cells, which was obtained by the following formula: percent
aggregation¼100 (1^[number of free cells])/(total number of cells).
Flow cytometry analysis T lymphocytes incubated with medium
alone, PMA or the activating anti-b1 integrin MoAbTS2/16 in the absence
or presence of 105 M rolipram for 24 h, were washed and incubated with
the biotinylated HUTS-21 MoAb, following by washing and labeling
with £uorescein isothiocyanate^avidin. The £uorescence produced by
the isotype-matched myeloma P3X63 supernatant was considered as
background. Cells were analyzed with a FACSCalibur £ow cytometer
(Becton-Dickinson, Mountain View, California), and results were
expressed as the mean £uorescence intensity. For the analysis of the
expression of activation antigens, mono-nuclear cells were stimulated with
5 mg PHA per mL for 48 h in the absence or presence or 105 M rolipram.
Then, cells were washed and incubated with the T3b anti-CD3, TP1/55
anti-CD69, TP1/6.2 anti-CD25, or the FG1/8 anti-CD98 MoAb, followed
by washing and labeling with an £uorescein isothiocyanate-labeled rabbit
anti-mouse IgG. Results were expressed as the percentage of positive cells.
Cell polarization assays Lymphocyte polarization assays were
performed as described (Nieto et al, 1997). Brie£y, 2106 T cells or T
lymphoblasts pretreated or not with di¡erent concentrations of rolipram,
were allowed to adhere to coverslips precoated with ¢bronectin for 1 h at
371C, 5% CO2 in 24-well plates (Costar, Cambridge, MA). Then, cells
were incubated with CXCL12 (100 ng per mL), IL-15 (10 ng per mL), or
medium alone for 30 min and ¢xed. Finally, cells were immunostained
with the TP1/24 anti-ICAM-3 MoAb followed by a £uorescein
isothiocyanate-tagged rabbit anti-mouse IgG (Coulter Corp., Hialeah,
Florida), and the proportion of uropod-bearing cells was calculated using
a Nikon Labophot-2 epi£uorescence microscope (Tokyo, Japan).
Microphotographs were obtained with a Nikon 850 Coolpix digital
camera.
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Lymphocyte-human umbilical vein endothelial cells (HUVEC)
adhesion assay HUVEC, obtained as described (Ja¡e et al, 1973), were
grown to con£uence on gelatin-coated coverslips in 24-well plates.
Peripheral blood T lymphocytes were pretreated or not with di¡erent
concentrations of rolipram for 8, 12, and 24 h. Then, cells were loaded
with the £uorescent probe BCECF-AM (Molecular Probes, Eugene,
Oregon), washed, resuspended at 2106 cells per mL in M199 medium
with 0.05% human serum albumin, and allowed to adhere to the
HUVEC monolayer (500 mL of lymphocyte suspension per well) in the
presence of CXCL12 (100 ng per mL) or medium alone for 5 or 10 min at
371C and 5% CO2. Then, coverslips were washed, ¢xed, and visualized in
a Nikon Labophot-2 microscope. The number of lymphocytes (£uorescent
cells) that were adhered to endothelium was counted in 10 random ¢elds
(63 oil-immersion objective), and results were expressed as the total
number of cells registered.
Transendothelial migration assays HUVEC were grown to
con£uence on Transwell inserts precoated with gelatin (Sigma) and
activated or not with TNF-a (20 ng per mL) for 6 h. T lymphocytes
(1106), pretreated or not for 12 h with di¡erent concentrations of
rolipram, were added to the upper chamber, and 600 mL of medium alone
or with CXCL12 (SDF-1, 50 ng per mL) were added to the lower
compartment. Cells were incubated for 16 h at 371C, and migrated cells
were recovered from the lower chamber, mixed with TruCount beads
(Becton-Dickinson) and counted during 1.0 min using a FACSCalibur
£ow cytometer. Results were expressed as the number of migrated cells.
In additional experiments,T cells (5106) pretreated or not with rolipram
were labeled with 100 mCi of Na51CrO4 during 1 h, washed and incubated
for an additional 60 min in an excess of culture medium. Then, labeled
cells were employed for migration assays as described above. At the end
of incubation, the radioactivity (cpm) in the upper and the bottom
chambers was determined in a gamma spectrometer (Packard, Ames,
Iowa) and results were expressed as the migration index.
RESULTS
Rolipram inhibits the adhesion of T cells to b1 and b2
integrin ligands in a concentration- and time-dependent
manner One of the events required for leukocyte migration
into in£amed tissues involves the integrin-mediated adhesion of
lymphocytes to endothelial cells (Gonza¤ lez-Amaro and Sa¤ nchez-
Madrid, 1999). We investigated the e¡ect of rolipram on T
lymphocyte adhesion to the b1 and b2 integrin ligands VCAM-1
and ICAM-1. As shown in Fig 1(A,B) basal adhesion of T
lymphoblasts to ICAM-1 and VCAM-1 was signi¢cantly
inhibited by rolipram at 105 M (po0.05 in both cases, Mann^
Whitney U test). In addition, the adhesion of T lymphoblasts to
ICAM-1 and VCAM-1 induced by the protein kinase C activator
PMA was also signi¢cantly inhibited by rolipram (po0.05).
Similar results were observed when experiments were conduced
using freshly isolated T lymphocytes and ICAM-1-coated plates
(Fig 1C). As expected, control blocking anti-CD11a (TP1/40, Fig
1A,C) and anti-a4 integrin chain (HP1/2, Fig 1B) MoAb
inhibited the adhesion of T cells to ICAM-1 and VCAM-1,
respectively. Next, we performed concentration- and time-
response experiments. We found that rolipram decreased the
PMA-induced adhesion of T cells to VCAM-1 and ICAM-1, in a
concentration-dependent fashion, with a signi¢cant e¡ect at 106
to 105 M for bothT lymphocytes and T lymphoblasts (Fig 2A).
On the other hand, kinetics experiments revealed that the e¡ect
of rolipram on PMA-stimulated T cell adhesion to VCAM-1 and
ICAM-1 was evident as early as after 4 h, with a maximal e¡ect
after 12 h (Fig 2B). The observed e¡ect of rolipram was not
related to cell death and T lymphocyte viability remained
una¡ected at all concentrations of rolipram tested (10^7^103 M)
and after 24 h of incubation (Fig 2C). Likewise, no signi¢cant
e¡ect of rolipram on the apoptosis of T cells or T lymphoblasts
was observed (Fig 2C). Similar results were obtained at 6 and 12
h of incubation with rolipram (data not shown).
E¡ect of rolipram on b1 integrin activation and b1 integrin-
induced homotypic aggregation of T lymphocytes The
inhibitory e¡ect of rolipram on the adhesion of T lymphocytes
to integrin ligands prompted us to explore whether the
activation state of integrins was a¡ected by this drug. By using
the HUTS-21 MoAb, which speci¢cally recognizes an activation
Figure1. Rolipram inhibits the adhesion of T cells to b1 and b2 in-
tegrin ligands.T lymphoblasts (A,B) or T cells (C) were incubated in the
presence or absence of rolipram (105 M) for 24 h, then stimulated with or
without PMA (20 ng per mL) and allowed to adhere to recombinant
ICAM-1-coated plates (A,C) or VCAM-1-coated plates (B). Blocking anti-
CD11a (TP1/40) (A,C) and anti-VLA-4 (HP1/2) (B) were added to inhibit
cell binding to ICAM-1 (A,C) and VCAM-1 (B), respectively. Finally, the
percentage of cell adhesion was determined by crystal violet staining, as
described in Materials and Methods. Values of cell adhesion correspond to
the arithmetic mean7SD of ¢ve independent experiments. *po0.05 com-
pared with basal; **po0.05 compared with PMA.
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neoepitope on b1 integrins, we observed that rolipram at 10
5 M
signi¢cantly inhibited PMA-induced activation of b1 integrins
(po0.05), but had no e¡ect on the basal levels of integrin
activation (Fig 3A). In contrast, the activation of these adhesion
receptors induced by the activatingTS2/16 MoAb was no a¡ected
by rolipram (Fig 3A). As in the cell adhesion assays, the maximal
e¡ect of rolipram on integrin activation was observed at 12 to
24 h (data not shown).
To analyze further the regulatory role of rolipram on b1
integrin-mediated adhesion of T lymphocytes, we explored the
e¡ect of this drug on the homotypic aggregation of T cells, a
process that involves both cell adhesion and cell migration
(Serrador et al, 1998). As shown in Fig 3(B) rolipram at 105 M
for 12 h signi¢cantly inhibited the homotypic aggregation of T
lymphocytes induced by the Lia1/2 anti-b1 integrins, and the
HP1/7 anti-a4 integrin chain MoAb (po0.05).
E¡ect of rolipram on the activation of T cells As activation
of Tcells is a key event required for the expression and activation
of adhesion molecules that mediate the extravasation of
lymphocytes (D|¤ az-Gonza¤ lez and Sa¤ nchez-Madrid, 1998), we
evaluated the e¡ect of rolipram on the PHA-induced expression
of the activation antigens CD25, CD69, and CD98.We found that
rolipram signi¢cantly inhibited the expression of all activation
antigens studied on the surface of PHA-stimulated T
lymphocytes (po0.05 in all cases) (Fig 4). As expected, rolipram
had no e¡ect on CD3 or CD45 levels (Fig 4), indicating that this
drug selectively inhibits the expression of cell surface markers
that are upregulated during T cell activation.
Rolipram inhibits T lymphocyte polarization induced
by IL-15 and CXCL12 In order to assess T lymphocyte
polarization, cells were immunostained for ICAM-3, a molecule
that redistributes to the uropod, and the proportion of uropod-
bearing cells was calculated. Rolipram signi¢cantly reduced the
Figure 2. Concentration- and time-dependent analyses of e¡ect of
rolipram on adhesion of T cells to ICAM-1 and VCAM-1 and on
the induction of cell death. T cells pretreated with rolipram at the indi-
cated doses for 24 h (A), or for the speci¢ed periods of time at 105 M (B)
were stimulated with PMA and then were allowed to adhere to recombi-
nant ICAM-1, or VCAM-1-coated plates. Then, the percentage of cell ad-
hesion was determined by crystal violet staining, as described in Materials
and Methods. Data of a representative experiment out of three are shown.
(C,D) Lack of signi¢cant e¡ect of rolipram on T cell viability and apopto-
sis. T lymphocytes were treated as in (A) and cell viability was assessed by
trypan blue dye exclusion (C), and apoptosis byTUNEL and £ow cytome-
try. Data of a representative experiment of four are shown.
Figure 3. E¡ect of rolipram on b1 integrin activation and b1 integ-
rin-induced homotypic aggregation of T cells. (A) T lymphocytes
were incubated in the presence or absence of 105 M rolipram and then
stimulated with PMA (20 ng per mL) or the activating MoAb TS2/16.
Thereafter, b1 integrin activation was assessed by £ow cytometry using
the HUTS-21 MoAb. Data correspond to the arithmetic mean7SD of
mean £uorescence intensity of ¢ve independent experiments. (B) T lym-
phocytes were incubated with the pro-aggregatory Lia1/2 anti-b1 integrins,
and HP1/7 anti-a4 integrin chain MoAb with or without rolipram 10
5 M.
After an incubation period of 3 h, the percentage of aggregated cells was
determined as described in Materials and Methods. Data correspond to the
arithmetic mean7SD of the percentage of aggregated cells of ¢ve inde-
pendent experiments. *po0.05 compared with PMA; **po0.05 compared
with Lia1/2 alone; ***po0.05 compared with HP1/7 alone.
Figure 4. Rolipram inhibits the expression of CD69, CD25, and
CD98 activation antigens by PHA-stimulated lymphocytes. Mono-
nuclear cells were stimulated with 5 mg PHA per mL for 48 h with or
without 105 M rolipram. Then, the expression of CD69, CD25, and
CD98 activation antigens, and CD3 and CD45 was assessed by £ow cyto-
metry, as described in Materials and Methods. Data correspond to the arith-
metic mean 7SD of the percentage of positive cells of ¢ve independent
experiments. *po0.05 compared with PHA alone.
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polarization of peripheral blood T lymphocytes induced by
the chemokine CXCL12, and the chemotactic cytokine IL-15
(po0.05) (Fig 5). This e¡ect was concentration-dependent, with
a signi¢cant inhibition at 106 to 105 M. Kinetics experiments
with 105 M rolipram revealed that its inhibitory e¡ect on T cell
polarization was evident after 8 h of incubation, with a maximal
e¡ect at 24 h (data not shown). In contrast, rolipram had no e¡ect
on the spontaneous polarization of T lymphocytes (Fig 5A). This
drug also signi¢cantly inhibited IL-15- and CXCL12-induced
polarization of T lymphoblasts as well as the baseline
polarization of these cells (po0.05) (Fig 5B).
Rolipram inhibits transendothelial migration As we found
that rolipram inhibited lymphocyte polarization in response
to CXCL12 and IL-15, we decided to assess the e¡ect of this
drug on the adhesion of T lymphocytes to endothelial cells and
their transendothelial migration. As expected, rolipram inhi-
bited adhesion of both resting and CXCL12-stimulated T
lymphocytes to endothelial cells in a concentration-dependent
fashion (Fig 6A). This e¡ect was observed after 8, 12, or 24 h of
rolipram treatment and at 5 or 10 min of T cell/HUVEC
interaction (Fig 6A and data not shown). In addition, the basal
(Fig 6B) as well as CXCL12-induced (Fig 6C) transendothelial
migration of T lymphocytes was signi¢cantly inhibited by
rolipram (po0.05). This e¡ect was observed when both resting
and TNF-a-activated endothelial cells were used (Fig 6B,C).
Similar results were obtained when migration assays were
performed with 51Cr-labeled T cells and the results expressed as
the migration index (Fig 6D). Under such experimental
conditions, however, a more evident e¡ect of CXCL12 on T cell
chemotaxis was observed.
All these experiments were performed at 12 h of incubation
with rolipram, and additional experiments showed that this
drug had a similar e¡ect at 24 h (data not shown). As in the case
of rolipram alone, the di¡erent treatments employed did not
signi¢cantly a¡ect the viability of the migrated cells (data not
shown).
DISCUSSION
There is accumulating evidence that PDE inhibitors represent an
interesting group of anti-in£ammatory and immunomodulatory
agents with great potential in the treatment of immune-mediated
skin diseases (Bruynzeel et al, 1998). In this regard, it has been
described that the nonspeci¢c PDE inhibitor pentoxifylline has
Figure 5. Rolipram inhibits T lymphocyte polarization induced by
IL-15 and CXCL12. Peripheral blood T lymphocytes (A) or T lympho-
blasts (B), pretreated with the indicated concentrations of rolipram, were
allowed to adhere to ¢bronectin 80-coated coverslips and then stimulated
with CXCL12 (100 ng per mL), IL-15 (10 ng per mL), or medium alone.
Thereafter, cell polarization was assessed by ICAM-3 immunostaining, as
described in Materials and Methods. Data of a representative experiment of
¢ve performed are shown. Images from a representative experiment of
CXCL12-induced polarization of T lymphocytes in the presence (D) or
absence (C) of rolipram are also shown. Note the scarcity of lymphocytes
with ICAM-3 redistributed to a cellular pole (polarized cells) in (D) com-
pared with (C).
Figure 6. Rolipram interferes with the adhesion of T cells to en-
dothelial cells and their transendothelial migration. (A) BCECF-
loaded T lymphocytes pretreated with the indicated concentrations of roli-
pram for 24 h were allowed to adhere to resting HUVEC in the presence or
not of CXCL12 (100 ng per mL) for 10 min. Thereafter, cell adhesion was
quanti¢ed by £uorescence microscopy, as described inMaterials and Methods.
(B,C). T lymphocytes incubated in the presence or absence of 105 M roli-
pram for 24 h were poured in the upper compartment of Transwell chemo-
taxis chambers. The upper side of the Transwell membrane was precoated
with a con£uent monolayer of HUVEC that was treated with or without
20 ng per mL TNF-a for 4 h. Basal (B) and CXCL12-induced (C) migra-
tion of T lymphocytes was quanti¢ed by £ow cytometry as described in
Materials and Methods. Data correspond to the arithmetic mean7SD of ad-
hered cells (A) or migrated cells (B,C) of ¢ve independent experiments. (D)
Migration assays were performed as in (B) and (C), but T cells were labeled
with Na51CrO4 and results were expressed as the migration index. Data
correspond to the arithmetic mean7SD of migration index of four inde-
pendent experiments. *po0.05 compared with untreated cells.
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a bene¢cial e¡ect in allergic hypersensitivity reactions, graft ver-
sus host disease, leprosy reaction, and Schamberg’s disease (Sam-
laska andWin¢eld, 1994; Kano et al, 1997; Moraes et al, 2000). It is
likely, however, that the usual doses of this drug are not always
su⁄cient to obtain the tissue concentrations necessary to exert
the di¡erent anti-in£ammatory e¡ects described in vitro for this
PDE inhibitor (Wang et al, 1997; Gonza¤ lez-Amaro et al, 1998b;
Dom|¤ nguez-JimeŁ nez et al, 2002). Therefore, we decided to assess
in vitro the anti-in£ammatory properties of rolipram, a potent
and selective PDE inhibitor. Interestingly, we have found that
low concentrations of this drug are able to inhibit di¡erent key
immune phenomena, including lymphocyte activation, polariza-
tion, adhesion, and transendothelial migration. As we have pre-
viously found for pentoxifylline (Gonza¤ lez-Amaro et al, 1998b),
the e¡ect of rolipramwas not related to the induction of acciden-
tal (necrosis) or programmed cell death (apoptosis).
Integrins, mainly those from b2 subfamily andVLA-4, play an
essential part in extravasation of leukocytes towards in£amma-
tory foci (Gonza¤ lez-Amaro et al, 1998a; Gonza¤ lez-Amaro and
Sa¤ nchez-Madrid, 1999). It has been described that the LFA-1/
ICAM-1 adhesion pathway is involved in cell^cell interactions
and the ¢rm adhesion of leukocytes to endothelial cells (Postigo
et al, 1993). In addition, the interaction between VLA-4 and
VCAM-1 is essential for the rolling of lymphoid cells on acti-
vated endothelium, both in vivo and in vitro (Johnston et al, 1996).
We found that rolipram inhibits the adhesion of T cells to the b1
and b2 integrin ligands VCAM-1 and ICAM-1. A signi¢cant in-
hibition was seen at 106 to 105 M for both T lymphocytes and
T lymphoblasts. These concentrations are signi¢cantly lower than
those required for pentoxifylline to inhibit the adhesion of Tcells
(104^103 M) (Gonza¤ lez-Amaro et al, 1998b). Accordingly, it has
been described that 105 M rolipram inhibits the adhesion of
neutrophils to endothelial cells in vitro (Derian et al, 1995), and
the migration of eosinophils induced by antigenic challenge
in vivo (Silva et al, 2001).
As lymphocyte adhesiveness is closely related to the activation
state of these cells, we studied the e¡ect of rolipram on the ex-
pression of activation markers on the surface of T cells.We found
that the PHA-induced expression of CD69, CD25, and CD98 on
the surface of T lymphocytes was signi¢cantly reduced by roli-
pram. In accordance, Kasyapa et al (1999) found a reduced expres-
sion of CD69 on the surface of T cells pretreated with rolipram
and stimulated with IL-15. Furthermore, our data are in agree-
ment with the study of Bielekova et al (2000) who reported that
rolipram downregulates the expression of class II major histo-
compatibility complex antigens and CD80 in monocytes and
lymphocytes upon activation with lipopolysaccharide or PHA.
On the other hand, we have found that rolipram inhibits the ac-
tivation of b1 integrins induced by PMA, but not by an activating
MoAb, which directly induces conformational changes of integ-
rins that increase the a⁄nity for their ligands. These data suggest
that rolipram a¡ects an intracellular signaling pathway that in-
volves protein kinase C and that results in integrin activation. In
this regard, it has been described that protein kinase C activation
is required for the expression of CD69 (Cebria¤ n et al, 1989), which
is inhibited by rolipram.
Lymphocyte activation induces cell polarization with the sub-
sequent redistribution of adhesion receptors to the uropod, a phe-
nomenon that is critical for lymphocyte chemotaxis and
recruitment to in£ammatory foci (del Pozo et al, 1996). Thus, the
inhibitory e¡ect of rolipram on the transendothelial migration of
T lymphocytes in response to CXCL12 (SDF-1) is in accordance
with its downregulatory e¡ect on lymphocyte polarization. It is
of interest that rolipram a¡ects the cell polarization induced by
two distinct stimuli, a chemokine and IL-15, that bind to very
di¡erent receptors. These data suggest that rolipram, as pentoxi-
fylline (Dom|¤ nguez-JimeŁ nez et al, 2002), a¡ects an intracellular
signaling pathway that is common to cell membrane receptors in-
volved in the induction of lymphocyte polarization. In agreement
with this point, Hidi et al (2000) reported that rolipram is able to
inhibit chemotaxis of T lymphocytes induced by two di¡erent
chemoattractants, IL-8 and platelet activation factor. It is worth
mentioning that CXCL12 is expressed by dendritic cells and en-
dothelium in human skin and may play an important part in the
recruitment of lymphocytes in in£ammatory skin diseases (Pablos
et al, 1999).Thus, the down-modulatory e¡ect of rolipram on lym-
phocyte migration may be bene¢cial for patients su¡ering from
skin diseases in which lymphocyte in¢ltration is a central feature,
such as psoriasis.
The phenomenon of intercellular adhesion that is observed
when leukocytes are incubated in vitro with MoAb that bind to
cell surface receptors is known as homotypic aggregation. It has
been proposed that the ligation of these molecules on the surface
of leukocytes triggers a cascade of intracellular signals that in-
duces cell migration and increase the a⁄nity of leukocyte integ-
rins for their ligands, leading to the process of intercellular
adhesion. These phenomena are critical for the development of
in£ammatory and immune responses and play an important part
in numerous biologic processes, both normal and pathologic. In-
terestingly, we have found that rolipram signi¢cantly reduces the
homotypic aggregation of T lymphocytes induced through b1
integrins. It is very likely that this e¡ect is consequence of the
inhibition by rolipram of lymphocyte chemotaxis and adhesion.
In addition, it is very feasible that this e¡ect signi¢cantly contri-
butes to the anti-in£ammatory activity of this drug.
In this work we have found that rolipram inhibits di¡erent
functions of T lymphocytes at concentrations 100 times lower
than those of pentoxifylline, a nonselective PDE inhibitor (Gon-
za¤ lez-Amaro et al, 1998b; Dom|¤ nguez-JimeŁ nez et al, 2002). In
agreement, Semmler et al (1993) reported that rolipram is 500-
fold more potent than pentoxifylline in the suppression of
TNF-a synthesis by human mononuclear cells induced by lipo-
polysaccharide. In addition, when a combination of a PDE inhi-
bitor and methylprednisolone was tested, the percentage of
inhibition of mitogen-induced lymphocyte proliferation
achieved with 105 M rolipramwas signi¢cantly greater than that
obtained with 104 M pentoxifylline (Briggs et al, 1999). Thus,
there are di¡erent data that clearly indicate the high potency of
rolipram on the inhibition of di¡erent key functions of immune
cells.
In summary, our data indicate that the type 4-speci¢c PDE in-
hibitor rolipram exerts, at low concentrations, important anti-in-
£ammatory and immunomodulatory e¡ects. Thus, this drug as
well as additional novel PDE inhibitors may be an important
tool for the treatment of diseases in which T cells are involved.
The clinical potential of rolipram in the treatment of immune-
mediated skin diseases is expected to become a fruitful area of
research. The development of a formula that allows the topical
application of this drug could be useful for the treatment of skin
diseases.
The invaluable help of Dr F. Sa¤ nchez-Madrid is fully appreciated. This work was
supported by a grant from CONACYT, MeŁ xico (to RG-A).
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